Zacks Investment Research downgraded shares of ATRICURE INC (ATRC) from OUTPERFORM to NEUTRAL on September 03, 2014, with a target price of $19.20.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ATRICURE INC (ATRC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment